Biotech | November 15, 2025
Merck to acquire Cidara Therapeutics for $9.2 billion
Diversifying its portfolio to include late-phase antiviral agent
Diversifying its portfolio to include late-phase antiviral agent
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
Relmada expects to initiate its Phase 3 program in the first half of 2026
Poviztra is a second brand of Wegovy
The device delivers clear, high-quality images to support accurate diagnoses across a broad range of patient groups
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
Subscribe To Our Newsletter & Stay Updated
